Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Steven Stein Biography and Net Worth

EVP of Incyte

Steven Stein joined Incyte as Senior Vice President and Chief Medical Officer in March 2015 and has over 10 years of experience in clinical development and regulatory interactions. Dr. Stein joined Incyte from Novartis Pharmaceuticals Corporation, where he most recently served as Senior Vice President, US Clinical Development & Medical Affairs at Novartis Oncology US. Dr. Stein previously worked at GlaxoSmithKline as Vice President, Global Oncology, Clinical Development and also as Head of Medicines Development for Hematology and Supportive Care. Dr. Stein earned his MD from the University of the Witwatersrand in Johannesburg, South Africa.

What is Steven H. Stein's net worth?: The estimated net worth of Steven H. Stein is at least $5.63 million as of January 4th, 2023. Dr. Stein owns 109,021 shares of Incyte stock worth more than $5,634,205 as of April 26th. This net worth estimate does not reflect any other assets that Dr. Stein may own. Additionally, Dr. Stein receives a salary of $1,220,000.00 as EVP at Incyte. Learn More about Steven H. Stein's net worth.
How old is Steven H. Stein?: Dr. Stein is currently 57 years old. There are 9 older executives and no younger executives at Incyte. The oldest executive at Incyte is Ms. Pamela M. Murphy, Vice President of Investor Relations & Corporate Communications, who is 73 years old. Learn More on Steven H. Stein's age.
What is Steven H. Stein's salary?: As the EVP of Incyte Co., Dr. Stein earns $1,220,000.00 per year. The highest earning executive at Incyte is Mr. Herve Hoppenot, CEO & Chairman, who commands a salary of $2,890,000.00 per year. Learn More on Steven H. Stein's salary.
How do I contact Steven H. Stein?: The corporate mailing address for Dr. Stein and other Incyte executives is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. Incyte can also be reached via phone at (302) 498-6700 and via email at [email protected]. Learn More on Steven H. Stein's contact information.
Has Steven H. Stein been buying or selling shares of Incyte?: Steven H. Stein has not been actively trading shares of Incyte in the last ninety days. Most recently, Steven H. Stein sold 28,399 shares of the business's stock in a transaction on Wednesday, January 4th. The shares were sold at an average price of $79.78, for a transaction totalling $2,265,672.22. Following the completion of the sale, the executive vice president now directly owns 109,021 shares of the company's stock, valued at $8,697,695.38. Learn More on Steven H. Stein's trading history.
Who are Incyte's active insiders?: Incyte's insider roster includes Dashyant Dhanak (EVP), Jonathan Dickinson (EVP), Wendy Dixon (Director), Barry Flannelly (EVP), Herve Hoppenot (President), Vijay Iyengar (EVP), Michael Morrissey (EVP), Maria Pasquale (EVP), Steven Stein (EVP), Paula Swain (EVP), Thomas Tray (Insider), and Wenquing Yao (EVP). Learn More on Incyte's active insiders.
Are insiders buying or selling shares of Incyte?: During the last twelve months, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 867 shares worth more than $54,750.60. The most recent insider tranaction occured on January, 2nd when EVP Vijay K Iyengar sold 657 shares worth more than $42,705.00. Insiders at Incyte own 17.5% of the company. Learn More about insider trades at Incyte.
Information on this page was last updated on 1/2/2024.

Steven H. Stein Insider Trading History at Incyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/4/2023	Sell	28,399	$79.78	$2,265,672.22	109,021
7/16/2020	Sell	766	$103.83	$79,533.78	96,234
7/8/2020	Sell	610	$108.56	$66,221.60	104,131
6/24/2019	Sell	8,357	$87.96	$735,081.72
8/29/2017	Sell	2,111	$125.00	$263,875.00	18,687
7/20/2017	Sell	6,485	$131.09	$850,118.65	19,356
6/20/2017	Sell	9,883	$125.00	$1,235,375.00	18,518
4/7/2017	Sell	32,000	$137.88	$4,412,160.00	41,648

Steven H. Stein Buying and Selling Activity at Incyte

Incyte Company Overview

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Today's Range

Now: $51.68

$50.87

$51.85

50 Day Range

MA: $56.78

$51.18

$61.00

2 Week Range

Now: $51.68

$50.27

$75.74

Volume

1,564,303 shs

Average Volume

1,723,511 shs

Market Capitalization

$11.60 billion

P/E Ratio

19.50

Dividend Yield

N/A

Beta

0.65

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

From Banyan Hill Publishing | Ad

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Watch my video for all of the details

Steven Stein Biography and Net Worth

What is Steven H. Stein's net worth?

How old is Steven H. Stein?

What is Steven H. Stein's salary?

How do I contact Steven H. Stein?

Has Steven H. Stein been buying or selling shares of Incyte?

Who are Incyte's active insiders?

Are insiders buying or selling shares of Incyte?